Gambaran Efek Samping dan Terapi Suportif Pasien Kanker Payudara Pasca Kemoterapi CAF di RSUP M.Djamil Padang

Rhandyka Rafli, Dessy Abdullah, Billy Yuliandri Sinulingga

Abstract


Latar belakang: pasien dengan kanker payudara sebagian besar akan menjalani kemoterapi sebagai terpai sistemik. Salah satu rejimen yang sering digunakan adalah Cyclophosphamide, Doxorubicin, 5-Fluorouracil (CAF) dapat menyebabkan berbagai efek samping yang tidak diinginkan yang perlu diatasi untuk meningkatkan kualitas hidup pasien. Tujuan: Untuk mengumpulkan data tentang efek samping yang sering terjadi dari kemoterapi berbasis CAF pada pasien kanker payudara di Rumah Sakit Dr. M. Djamil Padang dan terapi suportif setelah kemoterapi. Metode: Penelitian ini merupakan penelitian deskriptif observasional dengan desain simple random sampling. Data diambil melalui penelusuran rekam medis Rumah Sakit Umum Pusat Dr. M. Djamil Padang. Hasil: didapatkan 52 pasien sebagai sampel penelitian ini. Efeksamping yang paling banyak adalah leukopenia (50%).Efeksamping yang paling sedikit adalah mual (3,8%) dan toksisitas ginjal (1,9%). Terapisuportif yang paling banyak adalah injeks ileukogen (50%).Terapi suportif yang paling jarang adalah antiemetik (3,8%) dan hesperidin (1,9%). Kesimpulan: Efeksamping yang paling banyak dari  kemoterapi berbasis CAF adalah lekopenia. Efek samping mualsangat sedikit didapatkan.Terapi suportif yang paling banyak adalahi njeksi leukogen


Keywords


Kemoterapi, Efek samping, Terapi supportif

Full Text:

PDF

References


. [1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.,” CA. Cancer J. Clin., vol. 68, no. 6, pp. 394–424, Nov. 2018, doi: 10.3322/caac.21492.

. [2] R. Rafli and M. Anissa, “Peningkatan kualitas hidup pasien kanker dengan metastasis tulang yang menjalani radiasi paliatif,” Maj. Kedokt. Andalas, vol. 42, no. 1, p. 1, Jan. 2019, doi: 10.25077/mka.v42.i1.p1-10.2019.

. [3] T. A. Moo, R. Sanford, C. Dang, and M. Morrow, “Overview of Breast Cancer Therapy,” PET Clinics, vol. 13, no. 3. W.B. Saunders, pp. 339–354, Jul. 01, 2018, doi: 10.1016/j.cpet.2018.02.006.

. [4] Q. Lu et al., “Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center,” Cancer Commun., vol. 40, no. 5, pp. 222–233, May 2020, doi: 10.1002/cac2.12029.

. [5] S. Rivankar, “An overview of doxorubicin formulations in cancer therapy,” Journal of Cancer Research and Therapeutics, vol. 10, no. 4. J Cancer Res Ther, pp. 853–858, Oct. 01, 2014, doi: 10.4103/0973-1482.139267.

. [6] W. J. Gradishar et al., “NCCN Clinical Guidelines Breast Cancer (Version 5.2020): Invasive Breast Cancer,” 2020.

. [7] J. M. Peters and F. J. Gonzalez, “The Evolution of Carcinogenesis,” Toxicological Sciences, vol. 165, no. 2. Toxicol Sci, pp. 272–276, Oct. 01, 2018, doi: 10.1093/toxsci/kfy184.

. [8] C. Tri, W. Faisel, Y. Heriady, and A. Fitriangga, “GAMBARAN EFEK SAMPING KEMOTERAPI BERBASIS ANTRASIKLIN PADA PASIEN KANKER PAYUDARA DI RSUD DOKTER SOEDARSO PONTIANAK DESCRIPTION OF ANTHRACYCLINE-BASED CHEMOTHERAPY SIDE EFFECTS IN BREAST CANCER PATIENTS IN SOEDARSO GENERAL HOSPITAL PONTIANAK,” 2012. Accessed: Jan. 10, 2022. [Online]. Available: https://jurnal.untan.ac.id/index.php/jfk/article/view/1769.

. [9] H. Wulansari, T. Murti Andayani, and N. Wahyuningtyas, “Analisis Biaya Terapi Dan Gambaran Pengobatan Pada Pasien Kanker Payudara Di Instalasi Rawat Inap Rumah Sakit Umum Daerah Dr. Moewardi Di Surakarta Pada Tahun 2011,” 2013.

. [10] L. Yang et al., “Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: A case report,” BMC Cancer, vol. 15, no. 1, Nov. 2015, doi: 10.1186/s12885-015-1932-3.

. [11] A. M. Meredith and C. R. Dass, “Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism,” Journal of Pharmacy and Pharmacology, vol. 68, no. 6. Blackwell Publishing Ltd, pp. 729–741, Jun. 01, 2016, doi: 10.1111/jphp.12539.

. [12] A. Shafei et al., “A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer,” Biomedicine and Pharmacotherapy, vol. 95. Elsevier Masson SAS, pp. 1209–1218, Nov. 01, 2017, doi: 10.1016/j.biopha.2017.09.059.

. [13] S. Manohar and N. Leung, “Cisplatin nephrotoxicity: a review of the literature,” Journal of Nephrology, vol. 31, no. 1. Springer International Publishing, pp. 15–25, Feb. 01, 2018, doi: 10.1007/s40620-017-0392-z.

. [14] Z. Xiping, Y. Hongjian, Z. Dehong, H. Xiangming, Y. Xingfei, and L. Yongfeng, “EXPERIMENTAL STUDY OF CHEMOTHERAPY RELATED LEUKOCYTOPENIA TREATED BY VARIOUS PEROAL LEUCOCYTE INCREASING DRUGS,” African J. Tradit. Complement. Altern. Med. AJTCAM, vol. 14, no. 1, pp. 155–164, 2017, doi: 10.21010/ajtcam.v14i1.17.

. [15] X. E. Huang et al., “Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia,” Asian Pacific J. Cancer Prev., vol. 15, no. 19, pp. 8495–8497, 2014, doi: 10.7314/APJCP.2014.15.19.8495.

. [16] X. Chen, W. Wei, Y. Li, J. Huang, and X. Ci, “Hesperetin relieves cisplatin-induced acute kidney injury by mitigating oxidative stress, inflammation and apoptosis,” Chem. Biol. Interact., vol. 308, pp. 269–278, Aug. 2019, doi: 10.1016/j.cbi.2019.05.040.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2022 Baiturrahmah Medical Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Creative Commons License   Baiturrahmah Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.